Human recombinant interferonalpha-2b for management of idiopathic recurrent superficial pyoderma in dogs: a pilot study.

@article{Thompson2004HumanRI,
  title={Human recombinant interferonalpha-2b for management of idiopathic recurrent superficial pyoderma in dogs: a pilot study.},
  author={Lori A. Thompson and Terry L Grieshaber and Larry Glickman and Nita W. Glickman},
  journal={Veterinary therapeutics : research in applied veterinary medicine},
  year={2004},
  volume={5 1},
  pages={75-81}
}
The oral use of human recombinant interferonalpha-2b at 1,000 IU/ml/day appeared to provide only a transient benefit as compared with placebo for management of idiopathic recurrent superficial pyoderma in dogs. Further investigation using a larger population of dogs is needed to determine whether interferon is effective for long-term treatment of this condition. 

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Uses of interferon

M Schwassman
Derm Dialogue Winter 1999, • 1999

Modulation of a natural virus defense system by low concentrations of interferon at mucosal surfaces

GJ Stanton, TK Hughes, HK Heard
J Interferon Res (suppl 1):S99, • 1990

Strategies for management of recurrent pyoderma in dogs.

The Veterinary clinics of North America. Small animal practice • 1990

Interferons , immunity and chlamydiae

RJ Wills, HE Speigel, KF Soike
Interferon and Nonviral Pathogens . New York , Marcell Dekker , • 1988

Interferons, immunity and chlamydiae, in Byrne GI, Turco J (eds): Interferon and Nonviral Pathogens

GI Byrne
1988

RE: Toxoplasma, in Byrne GI, Turco J (eds): Interferon and Nonviral Pathogens

CM Black, JS Remington, McCabe
1988

Similar Papers

Loading similar papers…